BACKGROUND: Seneca Valley virus (NTX-010) is a non-recombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. PROCEDURES: In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 x 10(-4) to 10(4) viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 x 10(12) vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft. RESULTS: In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma panels. In vivo the most consistent activity was observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor, Wilms tumor, and glioblastoma panels. CONCLUSIONS: NTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existing testing and molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010. (c) 2010 Wiley-Liss, Inc.
BACKGROUND:Seneca Valley virus (NTX-010) is a non-recombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. PROCEDURES: In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 x 10(-4) to 10(4) viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 x 10(12) vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft. RESULTS: In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma panels. In vivo the most consistent activity was observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor, Wilms tumor, and glioblastoma panels. CONCLUSIONS:NTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existing testing and molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010. (c) 2010 Wiley-Liss, Inc.
Authors: M E Wilcox; W Yang; D Senger; N B Rewcastle; D G Morris; P M Brasher; Z Q Shi; R N Johnston; S Nishikawa; P W Lee; P A Forsyth Journal: J Natl Cancer Inst Date: 2001-06-20 Impact factor: 13.506
Authors: Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Tommy Alain; Anna Kossakowska; Patrick W K Lee Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: Kara L Norman; Matthew C Coffey; Kensuke Hirasawa; Douglas J Demetrick; Sandra G Nishikawa; Lisa M DiFrancesco; James E Strong; Patrick W K Lee Journal: Hum Gene Ther Date: 2002-03-20 Impact factor: 5.695
Authors: J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Matthew C Coffey; Bradley G Thompson; Chang-Soon Yoon; David M Waisman; Patrick W K Lee Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Linde A Miles; Laura N Burga; Eric E Gardner; Mihnea Bostina; John T Poirier; Charles M Rudin Journal: J Clin Invest Date: 2017-06-26 Impact factor: 14.808
Authors: J T Poirier; Irina Dobromilskaya; Whei F Moriarty; Craig D Peacock; Christine L Hann; Charles M Rudin Journal: J Natl Cancer Inst Date: 2013-06-05 Impact factor: 13.506